New hope for leukemia patients: drug targets hidden cancer cells after transplant
NCT ID NCT05940961
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests the drug inotuzumab ozogamicin in 42 adults with B-cell acute lymphoblastic leukemia who have minimal residual disease (MRD) after a stem cell transplant. MRD means a few cancer cells remain undetectable by standard tests but can cause relapse. The drug aims to turn MRD negative, which is linked to better long-term survival. Participants receive up to two 21-day cycles of the drug, and the study measures how well it clears MRD and improves survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- inotuzumab ozogamicin
- What this could lead to
- If successful, this could offer a way to eliminate leftover leukemia cells after transplant, potentially preventing relapse and improving survival.
- What could go wrong
- This is a small, early-phase trial with only 42 participants, so results may not apply broadly. The drug can cause serious side effects like liver damage or infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, 215006, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can donor immune cells be engineered to fight blood cancer?
- Can gut bacteria help rebuild immunity after stem cell transplants?
- Can a Chemo-Antibody combo beat a tough leukemia?
- Personalized chemo dosing may boost leukemia remission in kids
- Can a safer dose of an old drug shield vulnerable children from deadly fungal infections?
- Can pressurized oxygen boost cord blood transplants?